Clinical trials: Loss of Smell
Parkinson Disease
Role of Nasal Dysbiosis in Parkinson Disease
Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such…
- Trial name
- SMELLPARK (NCT04249245)
- Testing
- Nasal Swab
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Covid-19 Recurrent
Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.
- Trial name
- COVID-19 (NCT06544395)
- Testing
- Non invasive neuromodulation therapy, Manual therapy
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Clinica Gema Leon
Cancer, Sarcopenia
Personalized Cooking and Nutrition Guidance and Physical Activities Program to Reduce Muscle Loss in Advanced Cancer
People with advanced cancer often lose muscle over time. This can make them weaker, more tired, and reduce their quality of life. Many patients also struggle to eat because of changes in taste, smell, or appetite.
- Conditions
- Cancer, Sarcopenia, Muscle Mass Loss
- Trial name
- NCT07466862
- Testing
- Oncology Dietitian's Standard of Care, Personalized Culinary and Nutrition Therapy
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Gali Perel
Anosmia
Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia
ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia
- Trial name
- NCT04951362
- Testing
- intranasal spray ivermectin
- Where
- Egypt
- Volunteers
- 117 people
- Sponsor
- South Valley University
Parosmia
Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States.
- Trial name
- Stella (NCT06055270)
- Testing
- Stellate Ganglion Block
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Olfactory Disorder, Anosmia
Smell Changes & Efficacy of Nasal Theophylline
This study evaluates the efficacy and safety of nasal theophylline irrigation in treating smell loss related to a viral respiratory infection.
- Conditions
- Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use
- Trial name
- SCENT (NCT03990766)
- Testing
- Theophylline, Saline Nasal
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Brain Injuries, Olfaction Disorders
Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital
The aim of the study is to see whether patients with chronic smell impairment after brain injury benefit from a treatment that consists of corticosteroids, and then olfactory training in 3 months.
- Trial name
- NCT02565121
- Testing
- corticosteroids, olfactory stimulation
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- St. Olavs Hospital
Clinical Trial
Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy.
- Trial name
- NCT04569825
- Testing
- Ophtamesone
- Where
- Iraq
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Anbar
Covid19, Anosmia
Smell in Covid-19 and Efficacy of Nasal Theophylline
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even…
- Conditions
- Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic
- Trial name
- SCENT2 (NCT04789499)
- Testing
- Theophylline Powder
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Covid19
Singapore COVID-19 Chemosensory Tracking (SCCT) Study
The study aims to longitudinally track the onset, severity and recovery of changes in chemosensory acuity (smell and/or taste loss) among those suspected of COVID-19 infection.
- Trial name
- NCT04492904
- Testing
- Home-use Test and Follow-up Questionnaire
- Where
- Singapore
- Volunteers
- 102 people
- Sponsor
- Singapore Institute of Food and Biotechnology Innovation
Covid19, Anosmia
Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo.
- Conditions
- Covid19, Anosmia, Fever, Cough
- Trial name
- Hesperidin (NCT04715932)
- Testing
- Hesperidin
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Montreal Heart Institute